Updated on 2024/10/02

Information

 

写真a

 
MATSUMOTO TAKASHI
 
Organization
Kyushu University Hospital Urology Lecturer
School of Medicine Department of Medicine(Joint Appointment)
Title
Lecturer
Profile
泌尿器・前立腺・腎臓・副腎外科で臨床および研究に尽力しております。
External link

Degree

  • MD, PhD

Research Interests・Research Keywords

  • Research theme:Liquid biopsy for the patients with urothelial carcinoma

    Keyword:Liquid biopsy, Urothelial carcinoma

    Research period: 2020.4 - 2024.4

Awards

  • 第80回日本泌尿器科学会坂口賞

    2022.4   日本泌尿器科学会  

  • 第80回日本泌尿器科学会坂口賞

    2022.4   日本泌尿器科学会  

     More details

  • 2019 UBC Science Co-op Employer Recognition Award: supervisor award, University of British Columbia

    2019.2   University of British Columbia  

Papers

  • Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients. International journal

    Tokiyoshi Tanegashima, Masaki Shiota, Shigehiro Tsukahara, Jun Mutaguch, Shunsuke Goto, Satoshi Kobayashi, Takashi Matsumoto, Masatoshi Eto

    The Prostate   84 ( 14 )   1329 - 1335   2024.10   ISSN:0270-4137 eISSN:1097-0045

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Proton pump inhibitors (PPIs) are widely used due to their affordability and minimal severe side effects. However, their influence on the efficacy of cancer treatments, particularly androgen receptor signaling inhibitors (ARSIs), remains unclear. This study investigates the impact of PPI usage on the treatment outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: A total of 117 mCRPC patients were retrospectively analyzed and divided into two groups based on the concomitant use of PPI at the initiation of ARSI treatment: PPI+ (n = 38) and PPI- (n = 79). Patient characteristics, including age at ARSI treatment administered, prostate-specific antigen (PSA) value at ARSI treatment administered, International Society of Urological Pathology grade group at prostate biopsy, metastatic site at ARSI treatment administered, prior docetaxel (DTX) treatment, and type of ARSI (abiraterone acetate or enzalutamide) were recorded. Progression-free survival (PFS), overall survival (OS), and PSA response rates were compared between the two groups. Patients were further stratified by clinical background to compare PFS and OS between the two groups. RESULTS: The PPI- group exhibited significantly extended PFS and a trend toward improved OS. For PSA response (reduction of 50% or more from baseline), the rates were 62.3% and 45.9% in the PPI- group and the PPI+ group, respectively. For deep PSA response (reductions of 90% or more from baseline), the rates were 36.4% and 24.3% in the PPI- group and the PPI+ group, respectively. The effects were consistent across subgroups divided by prior DTX treatment and type of ARSI administered. CONCLUSIONS: The administration of PPIs appears to diminish the therapeutic efficacy of ARSIs in mCRPC patients. Further prospective studies are needed to confirm these findings and explore the biological mechanisms involved.

    DOI: 10.1002/pros.24769

    Web of Science

    Scopus

    PubMed

    researchmap

  • Optimization of Extended Pelvic Lymph Node Dissection Side for Prostate Cancer.

    Shiota M, Shimbo M, Tsukahara S, Tanegashima T, Mutaguchi J, Goto S, Kobayashi S, Matsumoto T, Hattori K, Endo F, Eto M

    Annals of surgical oncology   2024.9   ISSN:1068-9265

     More details

    Language:English  

    DOI: 10.1245/s10434-024-16294-6

    PubMed

  • Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator-activated receptor promotes enzalutamide resistance in prostate cancer. International journal

    Masaki Shiota, Miho Ushijima, Shigehiro Tsukahara, Shohei Nagakawa, Tatsunori Okada, Tokiyoshi Tanegashima, Satoshi Kobayashi, Takashi Matsumoto, Masatoshi Eto

    Free radical biology & medicine   221   81 - 88   2024.8   ISSN:08915849

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Androgen receptor (AR)-targeting therapy induces oxidative stress in prostate cancer. However, the mechanism of oxidative stress induction by AR-targeting therapy remains unclear. This study investigated the mechanism of oxidative stress induction by AR-targeting therapy, with the aim to develop novel therapeutics targeting oxidative stress induced by AR-targeting therapy. Intracellular reactive oxygen species (ROS) was examined by fluorescence microscopy and flow cytometry analysis. The effects of silencing gene expression and small molecule inhibitors on gene expression and cytotoxic effects were examined by quantitative real-time PCR and cell proliferation assay. ROS induced by androgen depletion co-localized with peroxisomes in prostate cancer cells. Among peroxisome-related genes, PPARA was commonly induced by AR inhibition and involved in ROS production via PKC signaling. Inhibition of PPARα by specific siRNA and a small molecule inhibitor suppressed cell proliferation and increased cellular sensitivity to the antiandrogen enzalutamide in prostate cancer cells. This study revealed a novel pathway by which AR inhibition induced intracellular ROS mainly in peroxisomes through PPARα activation in prostate cancer. This pathway is a promising target for the development of novel therapeutics for prostate cancer in combination with AR-targeting therapy such as antiandrogen enzalutamide.

    DOI: 10.1016/j.freeradbiomed.2024.05.030

    Scopus

    PubMed

    researchmap

  • Functional outcomes in robot-assisted partial nephrectomy with three-dimensional images reconstructed from computed tomography: a propensity score-matched comparative analysis. International journal

    Satoshi Kobayashi, Keiji Tsukino, Jun Mutaguchi, Tokiyoshi Tanegashi, Shunsuke Goto, Takashi Matsumoto, Masaki Shiota, Masatoshi Eto

    Journal of robotic surgery   18 ( 1 )   314 - 314   2024.8   ISSN:1863-2483 eISSN:1863-2491

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Our objective was to investigate the long-term functional outcomes of robot-assisted partial nephrectomy (RAPN) combined with three-dimensional (3D) imaging. The 3D images, reconstructed using computed tomography, were introduced in RAPN procedures. The demographic, oncological, functional, and volumetric outcomes of 296 patients who underwent RAPN with and without 3D imaging between 2013 and 2021 were analyzed retrospectively. Propensity score matching (1:1) was performed to adjust for potential baseline confounders. After matching, 71 patients were allocated to each group. In the 3D RAPN (3DRPN) group, functional outcomes significantly improved: the number of patients with over 90% estimated glomerular filtration rate (eGFR) preservation rate (40 vs. 43, P = 0.044), eGFR preservation rate (88.0% vs. 91.6%, P = 0.006), the number of patients with chronic kidney disease (CKD) upstaging (26 vs. 13, P = 0.023), and split renal function preservation rate (operated kidney: 84.9% vs. 88.5%, P = 0.015). The 3DRPN group showed superiority in terms of >90% eGFR preservation (P = 0.010), CKD upstaging-free survival rates (P < 0.001), and volumetric outcomes (excess parenchymal volume: 27.9 vs. 17.7 mL, P = 0.030; parenchyma volume preservation rate: 81.6% vs. 88.8%, P = 0.006). Three-dimensional imaging was positively associated with eGFR preservation (P = 0.023, odds ratio: 2.34) and prevention of CKD upstaging (P = 0.013, odds ratio: 2.90). In this study, RAPN combined with 3D imaging underscored the preservation of eGFR > 90% and the prevention of CKD upstaging by improving the preservation rate of renal parenchyma and split renal function.

    DOI: 10.1007/s11701-024-02070-x

    Web of Science

    Scopus

    PubMed

    researchmap

  • Current status and future perspective of immunotherapy for renal cell carcinoma

    Leandro Blas, Keisuke Monji, Jun Mutaguchi, Satoshi Kobayashi, Shunsuke Goto, Takashi Matsumoto, Masaki Shiota, Junichi Inokuchi, Masatoshi Eto

    International Journal of Clinical Oncology   29 ( 8 )   1105 - 1114   2024.8   ISSN:1341-9625 eISSN:1437-7772

     More details

    Language:English  

    In the last decade, the standard treatment for advanced renal cell carcinoma (RCC) has evolved, mainly driven by the development and approval of immune checkpoint inhibitors (ICIs). Currently, ICI monotherapy and ICI-based combinations with tyrosine kinase inhibitors and targeted therapies against mammalian target of rapamycin or vascular endothelial growth factor have become new standard treatments for first-line and subsequent-line therapies. ICIs play an important role as an adjuvant postoperative therapy, and this field is the subject of active research. Furthermore, ongoing randomized controlled trials are investigating the clinical value of more intense treatments by combining multiple effective treatments for RCC. Additionally, novel biomarkers for prognosis have been investigated. This study reviews the current evidence on immunotherapy as a treatment for RCC patients, randomized controlled trials, and ongoing studies including RCC patients and recent findings, and discusses future perspectives.

    DOI: 10.1007/s10147-023-02446-3

    Web of Science

    Scopus

    PubMed

    researchmap

  • Independent validation of genetic risk model to progression after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer

    Shiota, M; Nagakawa, S; Tsukahara, S; Matsumoto, T; Tanegashima, T; Eto, M

    INTERNATIONAL JOURNAL OF UROLOGY   31 ( 8 )   945 - 947   2024.8   ISSN:0919-8172 eISSN:1442-2042

     More details

  • Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer. International journal

    Masaki Shiota, Satoshi Endo, Shigehiro Tsukahara, Tokiyosh Tanegashima, Satoshi Kobayashi, Takashi Matsumoto, Masatoshi Eto

    Endocrine-related cancer   31 ( 7 )   2024.7   ISSN:1351-0088 eISSN:1479-6821

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Androgen receptor signaling is crucial for the development of treatment resistance in prostate cancer. Among steroidogenic enzymes, 3β-hydroxysteroid dehydrogenases (3βHSDs) play critical roles in extragonadal androgen synthesis, especially 3βHSD1. Increased expression of 3βHSDs is observed in castration-resistant prostate cancer tumors compared with primary prostate tumors, indicating their involvement in castration resistance. Recent studies link 3βHSD1 to resistance to androgen receptor signaling inhibitors. The regulation of 3βHSD1 expression involves various factors, including transcription factors, microenvironmental influences, and post-transcriptional modifications. Additionally, the clinical significance of HSD3B1 genotypes, particularly the rs1047303 variant has been extensively studied. The impact of HSD3B1 genotypes on treatment outcomes varies according to the therapy administered, suggesting the potential of HSD3B1 genotyping for personalized medicine. Targeting 3βHSDs may be a promising strategy for prostate cancer management. Overall, understanding the roles of 3βHSDs and their genetic variations may enable the development and optimization of novel treatments for prostate cancer.

    DOI: 10.1530/ERC-24-0023

    Web of Science

    Scopus

    PubMed

    researchmap

  • Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer. International journal

    Leandro Blas, Masaki Shiota, Tokiyoshi Tanegashima, Satoshi Kobayashi, Takashi Matsumoto, Masatoshi Eto

    International journal of urology : official journal of the Japanese Urological Association   31 ( 7 )   829 - 831   2024.7   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/iju.15449

    Web of Science

    PubMed

    researchmap

  • Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer(タイトル和訳中)

    Blas Leandro, Shiota Masaki, Tanegashima Tokiyoshi, Kobayashi Satoshi, Matsumoto Takashi, Eto Masatoshi

    International Journal of Urology   31 ( 7 )   829 - 831   2024.7   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

  • Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy(タイトル和訳中)

    Blas Leandro, Shiota Masaki, Tanegashima Tokiyoshi, Tsukahara Shigehiro, Ueda Shohei, Mutaguchi Jun, Goto Shunsuke, Kobayashi Satoshi, Matsumoto Takashi, Inokuchi Junichi, Eto Masatoshi

    International Journal of Urology   31 ( 4 )   404 - 408   2024.4   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

  • Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy

    Blas, L; Shiota, M; Tanegashima, T; Tsukahara, S; Ueda, S; Mutaguchi, J; Goto, S; Kobayashi, S; Matsumoto, T; Inokuchi, J; Eto, M

    INTERNATIONAL JOURNAL OF UROLOGY   31 ( 4 )   404 - 408   2024.4   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publisher:International Journal of Urology  

    Background: Early detection of biochemical recurrence (BCR) after radical prostatectomy (RP) is crucial for early treatment and improving survival outcomes. The optimal prostate-specific antigen (PSA) monitoring remains unclear, and several models have been proposed. We aimed to externally validate four models for optimal PSA monitoring after RP and propose modifications to improve them. Methods: We reviewed the clinicopathological data of 896 patients who underwent robot-assisted RP between 2009 and 2022. We examined all PSA values and estimated the PSA value for four monitoring schedules at each time point in the virtual follow-up. We defined the ideal PSA for BCR detection between 0.2 and 0.4 ng/mL. Results: During the median follow-up of 21.4 months, 128 (14.3%) patients presented BCR. The original and modified Keio models, National Cancer Center Hospital model, and American Urological Association/American Society for Radiation Oncology model detected BCR in 14 (10.9%), three (2.3%), 12 (9.4%), and 11 (8.6%) patients with PSA >0.4 ng/mL. Most patients experienced BCR detected with PSA >0.4 ng/mL during the first year postoperative. The modification of interval within 6 months postoperative avoided BCR detection with PSA >0.4 ng/mL within the first year postoperative in 8/9 (88.9%), 1/2 (50.0%), 5/6 (83.3%), and 4/4 (100%) for the original and modified Keio models, National Cancer Center Hospital model, and American Urological Association/American Society for Radiation Oncology model, respectively. Conclusion: We validated four models for PSA monitoring after RP to detect BCR and suggested modifications to avoid detections out of the desired range of PSA. These modifications could help to establish an optimal PSA monitoring schedule after RP.

    DOI: 10.1111/iju.15379

    Web of Science

    Scopus

    PubMed

  • Clinical features and oncological outcomes of bladder cancer microsatellite instability(タイトル和訳中)

    Nagakawa Shohei, Shiota Masaki, Takamatsu Dai, Tsukahara Shigehiro, Matsumoto Takashi, Blas Leandro, Inokuchi Junichi, Oda Yoshihiro, Eto Masatoshi

    International Journal of Urology   31 ( 4 )   438 - 445   2024.4   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

  • An innovate segmentation system by implementing dilated convolution and red channel enhanced images in cystoscopic images

    Mutaguchi, J; Morooka, K; Goto, S; Kobayashi, S; Matsumoto, T; Shiota, M; Inokuchi, J; Eto, M

    EUROPEAN UROLOGY   85   S377 - S377   2024.3   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study

    Takafumi Fukushima, Keisuke Goto, Tetsutaro Hayashi, Kenichiro Ikeda, Tomoya Hatayama, Ryoken Yamanaka, Kyosuke Iwane, Ryo Tasaka, Yuki Kohada, Kenshiro Takemoto, Kohei Kobatake, Akihiro Goriki, Asuka Toshida, Hikaru Nakahara, Masanori Motonaga, Kentaro Tokumo, Yasutoshi Fujii, C Nelson Hayes, Wataru Okamoto, Toshio Kubo, Takashi Matsumoto, Masaki Shiota, Noboru Yamamoto, Yuji Urabe, Eiso Hiyama, Koji Arihiro, Takao Hinoi, Nobuyuki Hinata

    Japanese Journal of Clinical Oncology   54 ( 2 )   175 - 181   2024.2   ISSN:0368-2811 eISSN:1465-3621

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Oxford University Press (OUP)  

    Abstract

    Objective

    Comprehensive genomic profiling testing using a hybrid-capture next-generation sequencing is commonly used in clinical practice to employ precision medicine in cancer treatment worldwide. In this study, we aimed to analyze the profiles obtained using comprehensive genomic profiling testing that was performed in Japanese castration-resistant prostate cancer patients and to discuss the genetic findings in a real-world setting.

    Methods

    A total of 60 cases and 57 castration-resistant prostate cancer patients underwent comprehensive genomic profiling testing between 1 January 2021 and 31 December 2022. Four types of comprehensive genomic profiling testing were selected, and clinically significant cancer-specific gene alterations were identified.

    Results

    The median age of patients was 74 years, and the median prostate-specific antigen value at the time of submission was 18.6 ng/ml. Fifty-seven (95%) of 60 cases were metastatic castration-resistant prostate cancers, and 3 cases (5%) were non-metastatic. Among all genetic alterations, androgen-receptor alteration was the most frequently detected in 17 cases (28.3%), followed by 15 cases of TP53 (25.0%), 14 cases of CDK12 (23.3%), 10 cases of phosphatase and tensin homolog (16.7%) and 9 cases of ATM (15.0%) mutations. A total of 13 patients (21.7%) received systemic therapy according to the comprehensive genomic profiling testing results. Overall, the survival rate was significantly greater in the group treated through systemic therapy based on comprehensive genomic profiling testing compared with the group without new therapeutic treatment (P = 0.041).

    Conclusions

    Comprehensive genomic profiling testing is recommended in castration-resistant prostate cancer patients identified as resistant to standard therapy as this can provide a new therapeutic option.

    DOI: 10.1093/jjco/hyad148

    Web of Science

    PubMed

    researchmap

  • Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab. Reviewed International journal

    #Blas L, @Shiota M, @Tsukahara S, @Nagakawa S, @Matsumoto T, @Eto M.

    Clin Genitourin Cancer   2024.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Adverse Events of Cabozantinib Plus Nivolumab Versus Plus Nivolumab

    Blas, L; Shiota, M; Tsukahara, S; Nagakawa, S; Matsumoto, T; Eto, M

    CLINICAL GENITOURINARY CANCER   22 ( 1 )   e122 - e127.e1   2024.2   ISSN:1558-7673 eISSN:1938-0682

     More details

    Language:English   Publisher:Clinical Genitourinary Cancer  

    Introduction: Recently, many agents and combinations for metastatic and advanced renal cell carcinoma have been approved. This study aims to highlight the comprehensive differences in adverse events (AEs) between cabozantinib (CAB) plus nivolumab (NIVO) and ipilimumab (IPI) plus NIVO based on a real-world big dataset. Material and Methods: We downloaded AE datasets of IPI + NIVO and CAB + NIVO from the Food and Drug Administration Adverse Event Reporting System database. We used the Medical Dictionary for Regulatory Activities to treat each AE as a preferred term and grouped it into the System Organ Class (SOC). We performed logistic regression analyses to compare IPI + NIVO and CAB + NIVO. Results: The incidence rates of 7 types of toxicities were higher for CAB + NIVO than for IPI + NIVO. On the other hand, the incidence rates of 3 types of toxicities were higher for IPI + NIVO than for CAB + NIVO. Serious AEs were higher in patients receiving IPI + NIVO. Conclusion: Our findings suggest that both combination therapies presented a disproportionate distribution of toxicities in several SOC. These findings may help clinicians select suitable therapy for the individual and improve the safety profile in patients with advanced renal cell carcinoma receiving NIVO + IPI and NIVO + CAB in a real-world setting.

    DOI: 10.1016/j.clgc.2023.09.003

    Web of Science

    Scopus

    PubMed

  • Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy to the prostate. Reviewed International journal

    @Shiota M, @Tsukahara S, @Takamatsu D, @Tanegashima T, @Ueda S, #Blas L, @Goto S, @Kobayashi S, @Matsumoto T, @Inokuchi J, @Shioyama Y, @Eto M.

    Asian J Endosc Surg   2024.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy to the prostate(タイトル和訳中)

    Shiota Masaki, Tsukahara Shigehiro, Takamatsu Dai, Tanegashima Tokiyoshi, Ueda Shohei, Blas Leandro, Goto Shunsuke, Kobayashi Satoshi, Matsumoto Takashi, Inokuchi Junichi, Shioyama Yoshiyuki, Eto Masatoshi

    Asian Journal of Endoscopic Surgery   17 ( 1 )   ases.13279 - ases.13279   2024.1   ISSN:1758-5902

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

  • Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation. Reviewed International journal

    J Robot Surg   2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation. International journal

    Masaki Shiota, Shigehiro Tsukahara, Shohei Ueda, Jun Mutaguchi, Shunsuke Goto, Satoshi Kobayashi, Takashi Matsumoto, Leandro Blas, Keisuke Monji, Junichi Inokuchi, Masatoshi Eto

    Journal of robotic surgery   17 ( 6 )   2721 - 2728   2023.12   ISSN:1863-2483 eISSN:1863-2491

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The novel technique of lateral pelvic fascia preservation (LPFP) in robot-assisted radical prostatectomy (RARP) has been reported to improve urinary continence recovery. We aimed to investigate surgical and oncological outcomes after RARP using the LPFP technique and compare them with conventional RARP. This study included patients who underwent RARP with and without the LPFP technique. Time to urinary continence recovery was compared between the LPFP and non-LPFP groups using univariate, multivariate, and propensity-score matched analysis. Perioperative and postoperative outcomes were compared between the two groups using univariate analysis. We included 139 patients who underwent RARP, 68 in the LPFP group and 71 in the non-LPFP group. The LPFP technique was associated with a shorter time to urinary continence recovery, a shorter operative time and lower estimated blood loss. Surgical and oncological outcomes, including complications, pathological T-stage, surgical margin status, and biochemical recurrence-free survival, were comparable between the two groups. This study demonstrated that the LPFP technique improves urinary continence recovery and operative times without compromising surgical and oncological outcomes. The use of this technique in patients with clinically localized prostate cancer is recommended.

    DOI: 10.1007/s11701-023-01702-y

    Web of Science

    Scopus

    PubMed

    researchmap

  • Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment. Reviewed International journal

    #Blas L, @Shiota M, @Matsumoto T, @Hori Y, @Nakamura M, @Seki N, @Kuroiwa K, @Yokomizo A, @Morokuma F, @Kiyoshima K, @Eto M:

    Int J Urol   2023.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Bone‐modifying agents are protective for symptomatic skeletal events in Radium‐223 treatment

    Leandro Blas, Masaki Shiota, Takashi Matsumoto, Yoshifumi Hori, Motonobu Nakamura, Narihito Seki, Kentaro Kuroiwa, Akira Yokomizo, Futoshi Morokuma, Keijiro Kiyoshima, Masatoshi Eto

    International Journal of Urology   30 ( 11 )   1029 - 1034   2023.11   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    Introduction

    Radium‐223 (Ra‐223) dichloride therapy increases overall survival and delays time to the first symptomatic skeletal event (SSE) in patients with castration‐resistant prostate cancer (CRPC) and bone metastases. Bone‐modifying agents (BMA) reduce SSE in patients with bone metastasis, but there is little information on their use with Ra‐223. This study aimed to investigate the effect of BMA on SSE in patients with bone metastatic CRPC treated with Ra‐223 in real‐world practice.

    Methods

    We included 73 patients treated with Ra‐223 from 10 institutions in Japan. Time to the first SSE was estimated using the Kaplan–Meier method and compared between groups using the log‐rank test. We used univariate analysis to ascertain the association between variables and SSE.

    Results

    During a median follow‐up of 12.7 months (interquartile range, 7–21.7), 12 (16.4%) patients presented SSE. Age and BMA use were different between men with and without SSE. The 1‐year SSE‐free survival rate from Ra‐223 treatment initiation was 82.4% (95% CI, 69.4%–90.2%). BMA use was associated with favorable SSE‐free survival (hazard risk, 0.23; 95% confidence interval, 0.061–0.85; p = 0.027). Two (4.7%) and seven (23.3%) patients presented symptomatic pathological bone fracture in groups with and without BMA use, respectively (p = 0.017).

    Conclusion

    This study stresses the importance of BMA use in patients with CRPC and bone metastases in Ra‐223 treatment.

    DOI: 10.1111/iju.15259

    Web of Science

    Scopus

    PubMed

    researchmap

  • 骨修飾薬はラジウム223治療における症候性骨関連事象に保護的である(Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment)

    Blas Leandro, Shiota Masaki, Matsumoto Takashi, Hori Yoshifumi, Nakamura Motonobu, Seki Narihito, Kuroiwa Kentaro, Yokomizo Akira, Morokuma Futoshi, Kiyoshima Keijiro, Eto Masatoshi

    International Journal of Urology   30 ( 11 )   1029 - 1034   2023.11   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    二塩化ラジウム223(Ra-223)で治療した骨転移した去勢抵抗性前立腺癌(CRPC)患者の症候性骨関連事象(SSE)に対する骨修飾薬(BMA)の効果について検討した。2016年6月~2018年12月に日本の10施設でRa-223治療を受けた20歳以上の患者を後ろ向きに調べた。SSEは骨痛緩和目的の外部照射、新たな症候性病的骨折、脊髄圧迫、または腫瘍関連の整形外科的介入と定義した。最初のSSEまでの時間をカプランマイヤー法で推定し、ログランク検定で群間比較した。単変量解析で変数とSSEとの関連を確認した。患者73例を解析した。追跡期間(中央値12.7ヵ月)中12例(16.4%)でSSEが発現した。SSEが発現した群は発現しなかった群より年齢が若く(68歳対74歳、p=0.01)、BMAの使用率が高かった(65%対25%、p=0.009)。Ra-223治療開始からの1年無SSE生存率は82.4%(95%CI 69.4%~90.2%)であった。BMAの使用は無SSE生存率の高さと関連した(ハザードリスク0.23、95%CI 0.061~0.85、p=0.027)。BMA使用群の2例(4.7%)、非使用群7例(23.3%)で症候性病的骨折が発現した(p=0.017)。以上より、Ra-223で治療した骨転移したCRPC患者におけるBMAの有用性が示唆された。

  • Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies. Reviewed International journal

    @Kashiwagi E, @Shiota M, @Inokuchi J, @Tsukahara S, @Imada K, @Monji K, @Goto S, @Matsumoto T, @Eto M:

    Anticancer Res   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • NR5A2/HSD3B1 pathway promotes cellular resistance to second-generation antiandrogen darolutamide. Reviewed International journal

    @Shiota M, @Ushijima M, @Tsukahara S, @Nagakawa S, #Blas L, @Takamatsu D, @Kobayashi S, @Matsumoto T, @Inokuchi J, @Eto M:

    Drug Resist Updat   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies

    Eiji Kashiwagi, Masaki Shiota, Junichi Inokuchi, Shigehiro Tsukahara, Kenjiro Imada, Keisuke Monji, Shunsuke Goto, Takashi Matsumoto, Masatoshi Eto

    Anticancer Research   43 ( 9 )   4249 - 4254   2023.9   ISSN:0250-7005 eISSN:1791-7530

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background/Aim: Testosterone is essential for prostate cancer development and growth. This study aimed to investigate the relationship between testosterone in seminal vesicles and prostate cancer incidence and its malignant phenotype. Patients and Methods: After obtaining institutional review board approval, seminal vesicle fluid samples were collected from patients who underwent prostatectomy or cystectomy. Pathological review demonstrated that 26 patients had benign prostate tissue and 149 had prostate cancer. First, testosterone levels in seminal vesicle fluid from benign prostate and prostate cancer samples were compared. Next, the relationship between pathological stage, International Society of Urological Pathology (ISUP) score, and testosterone concentrations in seminal vesicle fluid in the prostate cancer group were examined. Results: Testosterone in seminal vesicles was significantly higher in the prostate cancer group [median (range), 1.94 (0.17-4.32) ng/ml] than in the benign prostate group (mainly bladder cancer) [1.45 (0.60-2.78) ng/ml] (p=0.001). Testosterone in seminal vesicles showed no difference in relation to pathological stage (pT2 vs. pT3) or ISUP score (12 vs. 345) (p=0.480 and p=0.964, respectively). Neoadjuvant chemotherapy for other cancers (e.g., bladder or rectal cancer) significantly reduced testosterone in seminal vesicles (p=0.013). Multivariate regression analysis revealed that testosterone in seminal vesicles was significantly correlated with prostate cancer, and not with neoadjuvant chemotherapy (p=0.023, p=0.457, respectively). Conclusion: Testosterone in seminal vesicles may contribute to prostate cancer incidence, but has no relationship with pathological grading.

    DOI: 10.21873/anticanres.16618

    Web of Science

    Scopus

    PubMed

    researchmap

  • NR5A2/HSD3B1 pathway promotes cellular resistance to second-generation antiandrogen darolutamide. International journal

    Masaki Shiota, Miho Ushijima, Shigehiro Tsukahara, Shohei Nagakawa, Leandro Blas, Dai Takamatsu, Satoshi Kobayashi, Takashi Matsumoto, Junichi Inokuchi, Masatoshi Eto

    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy   70   100990 - 100990   2023.9   ISSN:1368-7646 eISSN:1532-2084

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    This study investigated cellular mechanisms in steroidogenesis responsible for treatment resistance to the novel antiandrogen agent darolutamide in prostate cancer. HSD3B1 was overexpressed in darolutamide-resistant cells and induced by darolutamide treatment and AR knockdown. Inversely, HSD3B1 knockdown increased cellular sensitivity to darolutamide. Similarly, its upstream regulator NR5A2 was up-regulated in darolutamide-resistant cells and induced by darolutamide treatment and AR knockdown. Inversely, NR5A2 knockdown and NR5A2 inhibitor ML180 decreased expression of various steroidogenic enzymes including HSD3B1, leading to increased cellular sensitivity to darolutamide. The NR5A2/HSD3B1 pathway promoted cellular resistance to darolutamide and targeting NR5A2/HSD3B1 pathway is a promising therapeutic strategy to overcome darolutamide resistance.

    DOI: 10.1016/j.drup.2023.100990

    Web of Science

    Scopus

    PubMed

    researchmap

  • Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naïve men. Reviewed International journal

    2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Adverse Events of Abiraterone Acetate vs Enzalutamide. Reviewed International journal

    #Blas L, @Shiota M, @Tsukahara S, @Nagakawa S, @Matsumoto T, @Eto M:

    Urol Pract   2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Adverse Events of Abiraterone Acetate vs Enzalutamide

    Blas, L; Shiota, M; Tsukahara, S; Nagakawa, S; Matsumoto, T; Eto, M

    UROLOGY PRACTICE   10 ( 4 )   360 - 370   2023.7   ISSN:2352-0779 eISSN:2352-0787

     More details

    Language:English   Publisher:Urology Practice  

    Introduction:This study aimed to highlight the comprehensive differences in adverse events between abiraterone and enzalutamide based on a big data data set.Methods:We downloaded adverse event data sets of abiraterone and enzalutamide from the Food and Drug Administration Adverse Event Reporting System database. We used the Medical Dictionary for Regulatory Activities to treat each adverse event as a preferred term and grouped it into the System Organ Class. Logistic regression analyses were performed to compare abiraterone and enzalutamide.Results:In total, we extracted 59,680 data sets. After exclusion by criteria, we included 26,015 reports on enzalutamide and 7,507 on abiraterone. Enzalutamide and abiraterone presented different toxicity profiles in most System Organ Classes. Overall, the reporting odds ratio indicated a higher incidence rate of serious adverse events for abiraterone than enzalutamide.Conclusions:In conclusion, our findings suggest that both drugs present a discrete and nonoverlapping toxicity profile that varies by System Organ Class and patient age. This data set confirms, for the most part, what has been reported in clinical trials as well as true real-world reports.

    DOI: 10.1097/UPJ.0000000000000404

    Web of Science

    Scopus

    PubMed

  • 生検歴のない男性において融合標的生検は前立腺癌の検出能を著しく改善する(Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naive men)

    Blas Leandro, Shiota Masaki, Tsukahara Shigehiro, Goto Shunsuke, Kinoshita Fumio, Matsumoto Takashi, Monji Keisuke, Kashiwagi Eiji, Inokuchi Junichi, Eto Masatoshi

    International Journal of Urology   30 ( 7 )   600 - 604   2023.7   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    前立腺癌(PC)が疑われる生検歴のない日本人男性において、MRI-超音波融合標的前立腺生検(TBx)と系統生検(SBx)を用いて、臨床的に重大なPC(csPC)の検出率を比較した。2020~2022年に日本の単一施設でPC疑いのためにMRI-TBx+SBxを行った143例(中央値70歳)を対象とするコホート研究を行った。csPCの定義は、国際泌尿器病理学会(ISUP)グレード群2以上(csPC-A)およびISUPグレード群3以上(csPC-B)とした。全PC検出率は、SBxで66.4%、MRI-TBxで67.8%であった。MRI-TBxはSBxに比べてcsPC検出率が有意に高く(csPC-Aは67.1 vs 58.7%、csPC-Bは49.6 vs 39.9%)、非csPC-A検出率が有意に低かった(0.6 vs 6.7%)。MRI-TBxの見逃し率はcsPC-Aは4.9%(7/143例)、csPC-Bは0.7%(1/143例)であったが、SBxではそれぞれ13.3%(19/143例)、4.2%(6/143例)であった。

  • Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naïve men

    Leandro Blas, Masaki Shiota, Shigehiro Tsukahara, Shunsuke Goto, Fumio Kinoshita, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto

    International Journal of Urology   30 ( 7 )   600 - 604   2023.7   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Objective: The precise diagnosis of prostate cancer (PC) is crucial to avoid underdiagnosis, overdiagnosis, and overtreatment. We aimed to compare clinically significant PC (csPC) detection between MRI/ultrasound fusion-targeted prostate (TBx) compared to systematic biopsy (SBx) in biopsy-naïve Japanese men. Methods: We included patients with suspect PC due to elevated PSA level or abnormal digital rectal examination, or both. csPC was defined as International Society Urological Pathology (ISUP) grade group ≥2 (csPC-A) and ISUP grade group ≥3 (csPC-B). Results: This study included 143 patients. Overall PC detection was 66.4% for SBx and 67.8% for MRI-TBx. MRI-TBx presented a significantly higher rate of csPC detection (csPC-A 67.1% vs. 58.7%, p = 0.04, and csPC-B 49.6% vs. 39.9%, p < 0.001) and significantly lower detection of non-csPC-A (0.6% vs. 6.7%). Importantly, MRI-TBx missed 4.9% (7/143) of csPC-A and only 0.7% (1/143) of csPC-B. On the other hand, SBx alone missed 13.3% (19/143) of csPC-A and 4.2% (6/143) of csPC-B. Conclusion: MRI-TBx significantly outperformed 12-cores SBx for csPC detection and decreased non-csPC detection in biopsy-naive men. Performing MRI-TBx without SBx would have missed some csPC, supporting that MRI-TBx synergizes with SBx to increase csPC detection.

    DOI: 10.1111/iju.15188

    Web of Science

    Scopus

    PubMed

    researchmap

  • Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy Invited Reviewed International journal

    @Ken Lee, @Masaki Shiota, @Dai Takamatsu, @Miho Ushijima, @Leandro Blas, @Ayami Okabe, @Shunichi Kajioka, @Shunsuke Goto, @Fumio Kinoshita, @Takashi Matsumoto, @Keisuke Monji, @Eiji Kashiwagi, @Junichi Inokuchi, @Yoshinao Oda, @Masatoshi Eto

    Int J Urol   2023.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/iju.15119. Epub 2022 Dec 7.

  • Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy. Reviewed International journal

    Int J Urol   2023.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • ロボット支援根治的前立腺摘出術後早期における拡大骨盤リンパ節郭清と尿失禁との相関(Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy)

    Lee Ken, Shiota Masaki, Takamatsu Dai, Ushijima Miho, Blas Leandro, Okabe Ayami, Kajioka Shunichi, Goto Shunsuke, Kinoshita Fumio, Matsumoto Takashi, Monji Keisuke, Kashiwagi Eiji, Inokuchi Junichi, Oda Yoshinao, Eto Masatoshi

    International Journal of Urology   30 ( 4 )   340 - 346   2023.4   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    ロボット支援根治的前立腺摘出術(RARP)後早期において拡大骨盤リンパ節郭清(ePLND)が尿失禁(UI)に及ぼす影響について検討した。海綿体神経温存を行わずにRARPを行った349例をePLND施行群186例(中央値66.5歳)とePLND非施行群163例(中央値68歳)に分類した。術後早期における排尿調節率のほか、国際前立腺症状スコア(IPSS)、リンパ節周囲脂肪組織(PLA)中のシナプトフィジンとチロシンヒドロラーゼ(TH)発現を評価した。ePLND施行群、非施行群とも術前にUIの発症はなく、術後1ヵ月における排尿調節率はePLND群が24.1%、非ePLND群が35.1%であり、ePLND群の方が有意に低かった。3、6、12ヵ月後の排尿調節率に有意な群間差はみられなかった。IPSS総スコアは1ヵ月後においてePLND群の方が有意に高く、3、6、12ヵ月後に有意差はなく、IPSS蓄尿スコアはいずれの時点でも有意な群間差はなく、IPSS排尿・排尿後症状スコアは1ヵ月後においてePLND群の方が有意に高値を示していた。多変量ロジスティック回帰分析では、前立腺容積とePLNDの施行がUI発症の独立予測因子として抽出された。ePLND群ではPLAにおいてシナプトフィジンとTH陽性神経線維が検出され、ePLNDの施行による脱神経がUI発症と関連することが示唆された。

  • Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report. International journal

    Masashi Kaitsumaru, Masaki Shiota, Dai Takamatsu, Leandro Blas, Takashi Matsumoto, Junichi Inokuchi, Yoshinao Oda, Masatoshi Eto

    International cancer conference journal   12 ( 2 )   131 - 136   2023.4   ISSN:2192-3183

     More details

    Language:English  

    A 67-year-old man with metastatic prostate cancer was treated with leuprorelin and enzalutamide, but presented radiographic progression after 1 year. Although docetaxel chemotherapy was initiated, liver metastasis appeared with elevation of nerve-specific enolase in serum. Pathological findings of needle biopsy of lymph node metastasis in the right inguinal region showed neuroendocrine carcinoma. FoundationOne CDx® using a biopsy sample of the prostate at initial diagnosis detected the BRCA1 mutation (deletion of intron 3-7), but BRACAnalysis® test revealed no BRCA mutation in germline. Then, olaparib treatment was initiated, resulting in remarkable remission of tumors, but comorbidity with interstitial pneumonia. This case suggested that olaparib could be effective for neuroendocrine prostate cancer with BRCA1 gene mutation, but may cause interstitial pneumonia.

    DOI: 10.1007/s13691-022-00592-5

    Web of Science

    PubMed

    researchmap

  • Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy. International journal

    Ken Lee, Masaki Shiota, Dai Takamatsu, Miho Ushijima, Leandro Blas, Ayami Okabe, Shunichi Kajioka, Shunsuke Goto, Fumio Kinoshita, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Yoshinao Oda, Masatoshi Eto

    International journal of urology : official journal of the Japanese Urological Association   30 ( 4 )   340 - 346   2023.4   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: To investigate the impact of extended pelvic lymph node dissection (ePLND) on urinary incontinence (UI) at early post-surgery robot-assisted radical prostatectomy (RARP). METHODS: Patients who underwent RARP without cavernous nerve sparing were included between 2014 and 2019. Patient data were obtained prospectively. The associations between ePLND and postoperative urinary continence were defined as a maximum of one daily pad use. International prostate symptom score (IPSS) was examined. Expression of synaptophysin and tyrosine hydroxylase (TH) in perilymph node adipose tissue (PLA) was evaluated by immunohistochemistry. RESULTS: In total, 186 and 163 patients underwent RARP with and without ePLND. Urinary continence rate at 1 month postoperatively among patients with ePLND was lower than those without ePLND (24.1% vs. 35.1%, p < 0.05), however, not significantly different at 3, 6, and 12 months after RARP (57.4 vs. 62.6%, 73.1 vs. 74.2%, and 83.0 vs. 81.2%, respectively). Total and voiding plus postvoiding IPSS scores at 1 month were higher in patients with ePLND than in those without ePLND (14.5 ± 0.5 vs. 13.6 ± 0.6, 7.0 ± 0.3 vs. 6.2 ± 0.4, respectively, p < 0.05). In univariate and multivariate analyses, larger prostate volume and ePLND were factors associated with an increased UI rate. Among patients who underwent ePLND, synaptophysin and TH-positive nerve fibers were detected in PLA. CONCLUSIONS: Detection of synaptophysin and TH-immunopositive nerves suggested denervation of sympathetic and peripheral nerves caused by ePLND might be associated with a higher UI rate and poor urinary symptoms at an early stage after RARP.

    DOI: 10.1111/iju.15119

    Web of Science

    Scopus

    PubMed

    researchmap

  • BRCA1変異を有する神経内分泌前立腺癌に対するオラパリブによる退縮後の間質性肺炎 1症例報告(Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report)

    Kaitsumaru Masashi, Shiota Masaki, Takamatsu Dai, Blas Leandro, Matsumoto Takashi, Inokuchi Junichi, Oda Yoshinao, Eto Masatoshi

    International Cancer Conference Journal   12 ( 2 )   131 - 136   2023.4

     More details

    Language:English   Publisher:シュプリンガー・ジャパン(株)  

    症例は67歳男性で、グリソンスコア5+5の前立腺腺癌と多発性の骨転移とリンパ節転移がみつかり、リュープロレリンとエンザルタミドの併用療法を受けた。1年後、鼠径部を含む多発リンパ節の腫大と骨転移が認められ、当科に紹介された。ドセタキセル+プレドニゾロンによる治療を開始した。さらに、脊髄転移が脊髄を圧迫し、両下肢麻痺を引き起こしたため、Th3、Th12、骨盤への放射線治療(29Gy/13分割)を行った。ドセタキセルを4サイクル行った後、多発肝転移とリンパ節転移のさらなる拡大を認めた。鼠径部のリンパ節転移の針生検の病理所見は神経内分泌癌であった。初診時の前立腺生検サンプルを用いたFoundationOne CDxではBRCA1変異(イントロン3-7欠失)が検出されたが、BRACAnalysis検査では生殖細胞系列にBRCA変異は認めなかった。その後、オラパリブ治療を開始した。1ヵ月後、リンパ節と肝臓の多発転移巣が縮小し、部分奏効を認めた。しかし、2ヵ月後、高熱と呼吸困難を呈した。CTスキャンで両側肺野にすりガラス影を認めた。間質性肺炎の併発と診断し、ステロイドパルス療法で治療した。肺炎は改善したが、全身状態は悪化し、緩和ケアと支持療法を行った。オラパリブ治療開始5ヵ月後に前立腺癌で死亡した。

  • Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study. Reviewed International journal

    @Matsumoto T, @Hori Y, @Shiota M, @Blas L, @Nakamura M, @Seki N, @Kuroiwa K, @Yokomizo A, @Morokuma F, @Kiyoshima K, @Eto M:

    Int J Urol   2023.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Association of MSI with recurrence prognosis after BCG therapy for non-muscle invasive bladder cancer

    Nagakawa, S; Shiota, M; Tsukahara, S; Matsumoto, T; Monji, K; Kashiwagi, E; Inokuchi, J; Eto, M

    CANCER SCIENCE   114   1967 - 1967   2023.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • 骨転移のある去勢抵抗性前立腺癌患者に対する塩化ラジウム223の臨床診療における有効性と安全性 多施設共同研究(Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study)

    Matsumoto Takashi, Hori Yoshifumi, Shiota Masaki, Blas Leandro, Nakamura Motonobu, Seki Narihito, Kuroiwa Kentaro, Yokomizo Akira, Morokuma Futoshi, Kiyoshima Keijiro, Eto Masatoshi

    International Journal of Urology   30 ( 2 )   139 - 146   2023.2   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    骨転移のある去勢抵抗性前立腺癌患者に対する塩化ラジウム223(Ra-223)の臨床診療における有効性と安全性ならびに全生存期間(OS)と関連する臨床パラメータを検討した。2016年6月~2018年12月に10施設でRa-223治療を受けた骨転移のある去勢抵抗性前立腺癌患者73例(中央値73歳)を対象とした。OS中央値は20.9ヵ月であった。アルカリホスファターゼ値は治療後に有意に低下した(p=0.03)。3例(4.1%)にグレード3以上の貧血、4例(5.5%)にグレード3以上の非病的骨折が発生した。病的骨折は9例(12.3%)に発生し、骨修飾薬非併用下では30例中7例(23.3%)に発生したのに対し、骨修飾薬併用下では43例中2例(4.7%)のみであった(p=0.03)。OS中央値は3サイクル以上の治療を受けた患者(27.2ヵ月、p<0.001[vs 2サイクル以下])、ヘモグロビン値12g/dL以上の患者(27.2ヵ月、p=0.001[vs 12g/dL未満])、骨痛のない患者(36.3ヵ月、p=0.004[vs 骨痛あり])で有意に長かった。

  • The efficacy of red channel enhanced images for AI segmentation of bladder tumors in Cystoscopic

    Mutaguchi, J; Morooka, K; Kinoshita, F; Matsumoto, T; Monji, K; Kashiwagi, E; Shiota, M; Inokuchi, J; Eto, M

    EUROPEAN UROLOGY   83   S847 - S848   2023.2   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Prognostic impact of CD73/adenosine receptor 2 (A2aR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features

    Takamatsu, D; Kiyozawa, D; Kohashi, K; Goto, S; Kinoshita, F; Matsumoto, T; Ri, K; Monji, K; Kashiwagi, E; Shiota, M; Inokuchi, J; Oda, Y; Eto, M

    EUROPEAN UROLOGY   83   2023.2   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Monitoring of cell-free DNA with digital PCR in muscle invasive bladder cancer

    Tsukahara, S; Shiota, M; Uchiumi, T; Matsumoto, T; Nagakawa, S; Kodama, K; Eto, M

    CANCER SCIENCE   114   2189 - 2189   2023.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Effectiveness and safety of radium‐223 dichloride in patients with castration‐resistant prostate cancer and bone metastases in real‐world practice: A multi‐institutional study Reviewed

    Takashi Matsumoto, Yoshifumi Hori, Masaki Shiota, Leandro Blas, Motonobu Nakamura, Narihito Seki, Kentaro Kuroiwa, Akira Yokomizo, Futoshi Morokuma, Keijiro Kiyoshima, Masatoshi Eto

    International Journal of Urology   30 ( 2 )   139 - 146   2023.2   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    Objective

    Radium‐223 (Ra‐223) dichloride is the bone‐targeted radioligand therapy that prolongs overall survival (OS) in patients with bone‐metastatic castration‐resistant prostate cancer (CRPC). We aimed to evaluate the safety and effectiveness of this treatment in real‐world practice.

    Methods

    We included Japanese men treated with Ra‐223 for bone‐metastatic CRPC from 10 institutions, retrospectively. Primary endpoint was OS. Secondary endpoint was maximum decline of alkaline phosphatase (ALP), lactate dehydrogenase, and prostate‐specific antigen values, the rate of adverse events, and time to pathological fracture after Ra‐223 treatment. Exploratory endpoint was the associations between clinical parameters and OS.

    Results

    In total, 73 men with bone metastatic CRPC treated with Ra‐223 were enrolled. The median OS was 20.9 months. ALP levels decreased significantly from pre‐treatment (p = 0.03). Anemia occurred in three (4.1%) patients. Grade ≥ 3 non‐pathological fractures occurred in four (5.5%) men. Nine (12.3%) patients presented pathological fracture; 7/30 (23.3%) were in men without concomitant use of a bone‐modifying agent (BMA) while 2/43 (4.7%) were in patients with concomitant BMA (p = 0.03). The median OS in patients with ≥3 cycles treatment (27.2 months, p &lt; 0.001) or hemoglobin ≥12 g/dl (27.2 months, p = 0.001) or absence of bone pain (36.3 months, p = 0.004) was significantly longer compared to those who with ≤2 cycles or hemoglobin&lt;12 g/dl or presence of bone paint, respectively.

    Conclusions

    This study has shown the outcomes of Ra‐223 treatment in real‐world practice, where the number of treatment cycles, baseline anemia and bone pain may be useful to predict OS in Ra‐223 treatment.

    DOI: 10.1111/iju.15078

    Web of Science

    Scopus

    PubMed

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/iju.15078

  • ctDNA guiding with hotspot mutation in PLEKHS1 further improves early prediction of recurrence in muscle-invasive bladder cancer

    Matsumoto, T; Tsukahara, S; Nagakawa, S; Monji, K; Kashiwagi, E; Shiota, M; Inokuchi, J; Keisuke, K; Eto, M

    EUROPEAN UROLOGY   83   S232 - S232   2023.2   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Validation of user-friendly models predicting extracapsular extension in prostate cancer patients Reviewed International journal

    @Leandro Blas, @Masaki Shiota, @Shohei Nagakawa, @Shigehiro Tsukahara, @Takashi Matsumoto, @Ken Lee, @Keisuke Monji, @Eiji Kashiwagi, @Junichi Inokuchi, @Masatoshi Eto

    Asian J Urol   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.ajur.2022.02.008. Epub 2022 Apr 22.

  • Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy Reviewed International journal

    @Leandro Blas, @Masaki Shiota, @Dai Takamatsu, @Fumio Kinoshita, @Takashi Matsumoto, @Ken Lee, @Keisuke Monji, @Eiji Kashiwagi, @Junichi Inokuchi, @Masatoshi Eto

    World J Urol   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00345-022-04245-3. Epub 2022 Dec 17.

  • Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy

    Leandro Blas, Masaki Shiota, Dai Takamatsu, Fumio Kinoshita, Takashi Matsumoto, Ken Lee, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto

    World Journal of Urology   41 ( 1 )   43 - 50   2023.1   ISSN:0724-4983 eISSN:1433-8726

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s00345-022-04245-3

    Web of Science

    Scopus

    PubMed

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s00345-022-04245-3/fulltext.html

  • CLINICAL STATISTICS AT THE UROLOGICAL DEPARTMENT OF KYUSHU UNIVERSITY HOSPITAL FOR THE PERIOD 2018-2020

    Shigetomo Yamada, Hidekazu Naganuma, Takashi Matsumoto, Ken Lee, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Masaki Shiota, Junichi Inokuchi, Masatoshi Eto

    Nishinihon Journal of Urology   85 ( 3 )   89 - 93   2023   ISSN:0029-0726

     More details

    Publishing type:Research paper (scientific journal)  

    A study of the clinical statistics at our department for the period 2018-2020 revealed the following results. 1) The number of outpatients was 41,442, including 2,823 new patients. The most common diseases among the new patients were urogenital malignant tumors 1,293 (45.8%), benign prostatic hyperplasia 303 (10.7%), neurogenic bladder 128 (4.5%), inflammatory diseases 122 (4.3%), and urolithiasis 104 (3.7%). 2) The total number of inpatients was 2,775 (2,175 males and 600 females), and the majority of them comprised males aged 60-79 years. The main disease among the inpatients was urogenital neoplasms 1,957 (70.5%). 3) A total of 1,662 cases underwent surgery, with 87 cases undergoing open surgery, 678 cases undergoing laparoscopic surgery, and 789 cases undergoing endourological surgery.

    Scopus

    researchmap

  • Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide Invited Reviewed International journal

    @Eiji Kashiwagi, @Masaki Shiota, @Ken Lee, @Keisuke Monji, @Hidekazu Naganuma, @Takashi Matsumoto, @Ario Takeuchi, @Junichi Inokuchi, @Masatoshi Eto

    JMA J   2022.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.31662/jmaj.2022-0096. Epub 2022 Sep 20.

  • Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer Reviewed International journal

    @Eiji Kashiwagi, @Masaki Shiota, @Hidekazu Naganuma, @Keisuke Monji, @Kenjiro Imada, @Ken Lee, @Takashi Matsumoto, @Ario Takeuchi, @Junichi Inokuchi, @Masatoshi Eto

    Int J Urol   2022.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/iju.14953. Epub 2022 Jun 18.

  • 前立腺癌患者の精嚢液中のテストステロン濃度は血清テストステロンよりも優れた勃起機能の指標である(Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer)

    Kashiwagi Eiji, Shiota Masaki, Naganuma Hidekazu, Monji Keisuke, Imada Kenjiro, Lee Ken, Matsumoto Takashi, Takeuchi Ario, Inokuchi Junichi, Eto Masatoshi

    International Journal of Urology   29 ( 10 )   1155 - 1162   2022.10   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    精嚢液中の因子が勃起機能に及ぼす影響を明らかにするため、精嚢液中の因子と勃起機能との関連を評価した。2017年5月~2020年8月に当院でロボット支援根治的前立腺摘除術を受けた限局性前立腺癌日本人患者を登録し、精嚢液サンプルを収集した。Sexual Health Inventory for Men(SHIM)、Erection Hardness Score(EHS)、および性的欲求の有無に関する独自の調査票の結果と、精嚢液中因子(テストステロン、PGE2、TGFβ1、8-OHdGの濃度)および血清テストステロン濃度との関連を調べた。患者134例(中央値67歳)を解析した。精嚢液テストステロン濃度はSHIMスコア17以上(勃起機能あり)の患者で17未満の患者より有意に高かったが(p=0.002)、血清テストステロン濃度に有意差はなかった(p=0.661)。多変量解析で、精嚢液テストステロン濃度とSHIMスコアとに有意な関連が認められた(オッズ比:2.137、95%CI:1.148~3.978、p=0.016)。以上から、精嚢液のテストステロン濃度は、前立腺癌患者の勃起機能を反映する可能性が示唆された。

  • エンザルタミド治療を行った前立腺癌患者において腰筋量は疲労および食欲不振の予測マーカーである(Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide)

    Kashiwagi Eiji, Shiota Masaki, Lee Ken, Monji Keisuke, Naganuma Hidekazu, Matsumoto Takashi, Takeuchi Ario, Inokuchi Junichi, Eto Masatoshi

    JMA Journal   5 ( 4 )   491 - 497   2022.10   ISSN:2433-328X

     More details

    Language:English   Publisher:(公社)日本医師会  

    2011年8月~2018年9月に日本の単一施設でエンザルタミド治療を行った去勢抵抗性前立腺癌(CRPC)患者67例(中央値73歳)を対象に、身体組成と主観的症状(疲労、食欲不振、疼痛、不眠症)の関連を後向きに検討した。エンザルタミド治療の開始前に行ったCT画像を用いて、体脂肪率、内臓脂肪率、腰筋量を算出した。腰筋量の中央値(160.1cm3/m)で高値群と低値群に分類した場合、腰筋量高値群ではグレード2以上の疲労が有意に増加し(オッズ比3.875、95%CI 1.016~17.134)、グレード2以上の食欲不振が有意に減少した(オッズ比0.093、95%CI 0.011~0.784)。エンザルタミド治療を行ったCRPC患者において、腰筋量は疲労および食欲不振の予測マーカーであることが示された。

  • Denervation caused by extended pelvic lymph node dissection worsens early urinary continence after robot-assisted radical prostatectomy

    Lee, K; Shiota, M; Takamatsu, D; Ushijima, M; Okabe, A; Kajioka, S; Goto, S; Kinoshita, F; Matsumoto, T; Monji, K; Kashiwagi, E; Inokuchi, J; Oda, Y; Eto, M

    INTERNATIONAL JOURNAL OF UROLOGY   29   22 - 22   2022.10   ISSN:0919-8172 eISSN:1442-2042

     More details

  • Androgen receptor mutations for precision medicine in prostate cancer

    Shiota, M; Akamatsu, S; Tsukahara, S; Nagakawa, S; Matsumoto, T; Eto, M

    ENDOCRINE-RELATED CANCER   29 ( 10 )   R143 - R155   2022.10   ISSN:1351-0088 eISSN:1479-6821

     More details

    Language:English   Publisher:Endocrine-Related Cancer  

    Hormonal therapies including androgen deprivation therapy and androgen receptor (AR) pathway inhibitors such as abiraterone and enzalutamide have been widely used to treat advanced prostate cancer. However, treatment resistance emerges after hormonal manipulation in most prostate cancers, and it is attributable to a number of mechanisms, including AR amplification and overexpression, AR mutations, the expression of constitutively active AR variants, intra-tumor androgen synthesis, and promiscuous AR activation by other factors. Although various AR mutations have been reported in prostate cancer, specific AR mutations (L702H, W742L/C, H875Y, F877L, and T878A/S) were frequently identified after treatment resistance emerged. Intriguingly, these hot spot mutations were also revealed to change the binding affinity of ligands including steroids and antiandrogens and potentially result in altered responses to AR pathway inhibitors. Currently, precision medicine utilizing genetic and genomic data to choose suitable treatment for the patient is becoming to play an increasingly important role in clinical practice for prostate cancer management. Since clinical data between AR mutations and the efficacy of AR pathway inhibitors are accumulating, monitoring the AR mutation status is a promising approach for providing precision medicine in prostate cancer, which would be implemented through the development of clinically available testing modalities for AR mutations using liquid biopsy. However, there are few reviews on clinical significance of AR hot spot mutations in prostate cancer. Then, this review summarized the clinical landscape of AR mutations and discussed their potential implication for clinical utilization.

    DOI: 10.1530/ERC-22-0140

    Web of Science

    Scopus

    PubMed

  • 治療抵抗性泌尿器癌における遺伝子解析と治療 九州大学病院泌尿器・前立腺・腎臓・副腎外科における泌尿器癌のがんゲノムプロファイリング検査の経験

    塩田 真己, 松元 崇, 李 賢, 猪口 淳一, 江藤 正俊

    西日本泌尿器科   84 ( 6 )   613 - 620   2022.8   ISSN:0029-0726

     More details

    Language:Japanese   Publisher:(一社)西日本泌尿器科学会  

    本邦でも2019年にがんゲノムプロファイル検査が保険承認され,がんゲノム医療が臨床実装されるに至った。九州大学病院もがんゲノム医療中核拠点病院としてがんゲノム医療において中心的な役割を担っている。そこで,がんゲノムプロファイル検査およびその結果に基づく受療機会の提供についての我々の経験について報告する。対象は2019年6月から2021年10月までに九州大学病院泌尿器・前立腺・腎臓・副腎外科においてがんゲノムプロファイル検査を施行した症例を対象とし,患者背景,臨床情報,がんゲノムプロファイル検査結果を電子カルテから収集した。その結果,腎癌4症例,尿路上皮癌9症例,前立腺癌9症例でがんゲノムプロファイル検査が施行されていた。がんゲノムプロファイル検査の結果,5症例で遺伝子異常に基づく治療が推奨されたが,受療機会の創出に結びついたのは2症例のみであった。本邦におけるがんゲノム医療は徐々に普及しているが,受療機会の提供につながる症例は少なく,がんゲノム医療の課題と考えられる。保険診療での治療に加え,治験や臨床試験での受療機会の拡大を通じて,治療につながるような継続的な取り組みが求められている。(著者抄録)

  • ロボット支援根治的前立腺全摘除術における神経温存が切除断端陽性および生化学的再発リスクに及ぼす影響(Impact of nerve sparing in robot-assisted radical prostatectomy on the risk of positive surgical margin and biochemical recurrence)

    Komori Hiroki, Blas Leandro, Shiota Masaki, Takamatsu Dai, Matsumoto Takashi, Lee Ken, Monji Keisuke, Kashiwagi Eiji, Inokuchi Junichi, Eto Masatoshi

    International Journal of Urology   29 ( 8 )   824 - 829   2022.8   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    ロボット支援根治的前立腺全摘除術(RARP)での神経温存により切除断端陽性率や生化学的再発リスクが高まるかを検討した。2009~2021年に限局性前立腺癌の一次治療としてRARPを受けた患者を対象とした。ロジスティック回帰分析とCox比例ハザードモデルを用いた。患者814例(年齢中央値66歳)を解析した。片側神経温存は152例(18.6%)、両側神経温存は118例(14.5%)で行われた。術前因子を調整した多変量解析では、非神経温存と比較して、神経温存および両側神経温存が切除断端陽性のリスク増加と関連していた。切除断端陽性(部位を問わない)は生化学的再発リスク増加の独立危険因子であった。片側神経温存では、神経温存側の手術断端陽性が生化学的再発のリスク増加と関連したが、非神経温存側では関連がなかった。以上から、RARPでの神経温存では手術断端陽性に関連する生化学的再発リスクがあり、外科医は神経温存に適した患者を選択する必要があると考えられた。

  • Impact of nerve sparing in robot‐assisted radical prostatectomy on the risk of positive surgical margin and biochemical recurrence

    Hiroki Komori, Leandro Blas, Masaki Shiota, Dai Takamatsu, Takashi Matsumoto, Ken Lee, Keisuke Monji, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto

    International Journal of Urology   29 ( 8 )   824 - 829   2022.8   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    Objectives

    Nerve sparing may increase positive surgical margin rate during radical prostatectomy. Our objective was to analyze the positive surgical margin rate and location as well as its impact on biochemical recurrence according to nerve sparing procedure in robot‐assisted radical prostatectomy.

    Methods

    We included 814 patients treated with robot‐assisted radical prostatectomy between 2009 and 2021, and evaluated the impact of nerve sparing on positive surgical margin and biochemical recurrence using logistic regression and Cox models.

    Results

    Unilateral nerve sparing and bilateral nerve sparing were performed in 152 (18.6%) cases and 118 (14.5%) cases, respectively. On multivariable analysis, in addition to nerve sparing, bilateral nerve sparing, but not unilateral nerve sparing was associated with an increased risk of positive surgical margin compared with non‐nerve sparing. Positive surgical margin at any location increased the risk of biochemical recurrence. During unilateral nerve sparing, positive surgical margin in nerve sparing side, but not in non‐nerve sparing side was associated with increased risk of biochemical recurrence on multivariate analysis.

    Conclusions

    Taken together, surgeons need to notice an increased risk of biochemical recurrence associated with positive surgical margin when performing nerve sparing in robot‐assisted radical prostatectomy, and then need to choose the patients suitable for nerve sparing.

    DOI: 10.1111/iju.14900

    Web of Science

    Scopus

    PubMed

    researchmap

    Other Link: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/iju.14900

  • Activated protein kinase C-alpha as a simple test for urothelial cancer screening.

    Inokuchi, J; Murata, M; Kawano, T; Kang, JH; Kinoshita, F; Matsumoto, T; Monji, K; Kashiwagi, E; Takeuchi, A; Shiota, M; Eto, M

    JOURNAL OF CLINICAL ONCOLOGY   40 ( 16 )   E16552 - E16552   2022.6   ISSN:0732-183X eISSN:1527-7755

     More details

  • 経皮的針生検後に腎内播種を来したcT1a腎癌の一例

    持田 学, 木下 史生, 長沼 英和, 松元 崇, 李 賢, 門司 恵介, 柏木 英志, 武内 在雄, 塩田 真己, 猪口 淳一, 江藤 正俊, 高松 大, 小田 義直

    西日本泌尿器科   84 ( 増刊号2 )   182 - 182   2022.6   ISSN:0029-0726

     More details

    Language:Japanese   Publisher:(一社)西日本泌尿器科学会  

    researchmap

  • Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine. International journal

    Shigehiro Tsukahara, Masaki Shiota, Dai Takamatsu, Shohei Nagakawa, Takashi Matsumoto, Ryo Kiyokoba, Mikako Yagi, Daiki Setoyama, Nozomi Noda, Shinya Matsumoto, Tetsutaro Hayashi, Alberto Contreras-Sanz, Peter C Black, Junichi Inokuchi, Kenichi Kohashi, Yoshinao Oda, Takeshi Uchiumi, Masatoshi Eto, Dongchon Kang

    Scientific reports   12 ( 1 )   8535 - 8535   2022.5   ISSN:2045-2322

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Chemotherapy is a standard therapy for muscle-invasive bladder cancer (MIBC). However, genomic alterations associated with chemotherapy sensitivity in MIBC have not been fully explored. This study aimed to investigate the genomic landscape of MIBC in association with the response to chemotherapy and to explore the biological role of genomic alterations. Genomic alterations in MIBC were sequenced by targeted exome sequencing of 409 genes. Gene expression in MIBC tissues was analyzed by western blotting, immunohistochemistry, and RNA microarray. Cellular sensitivity to gemcitabine and gemcitabine metabolite was examined in bladder cancer cells after modulation of candidate gene. Targeted exome sequencing in 20 cases with MIBC revealed various genomic alterations including pathogenic missense mutation of DPYD gene encoding dihydropyrimidine dehydrogenase (DPD). Conversely, high DPYD and DPD expression were associated with poor response to gemcitabine-containing chemotherapy among patients with MIBC, as well as gemcitabine resistance in bladder cancer cells. DPD suppression rendered cells sensitive to gemcitabine, while DPD overexpression made cells gemcitabine-resistant through reduced activity of the cytotoxic gemcitabine metabolite difluorodeoxycytidine diphosphate. This study revealed the novel role of DPD in gemcitabine metabolism. It has been suggested that DPYD genomic alterations and DPD expression are potential predictive biomarkers in gemcitabine treatment.

    DOI: 10.1038/s41598-022-12528-3

    Web of Science

    Scopus

    PubMed

    researchmap

  • Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine Reviewed International journal

    @Shigehiro Tsukahara, @Masaki Shiota, @Dai Takamatsu\, @Shohei Nagakawa, @Takashi Matsumoto, @Ryo Kiyokoba, @Mikako Yagi, @Daiki Setoyama, @Nozomi Noda, @Shinya Matsumoto, @Tetsutaro Hayashi, @Alberto Contreras-Sanz, @Peter C Black, @Junichi Inokuchi, @Kenichi Kohashi, @Yoshinao Oda, @Takeshi Uchiumi, @Masatoshi Eto, @Dongchon Kang

    Sci Rep   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41598-022-12528-3.

  • An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer Reviewed International journal

    @Miho Ushijima, @Masaki Shiota, @Takashi Matsumoto, @Eiji Kashiwagi, @Junichi Inokuchi, @Masatoshi Eto

    Cancer Sci   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.15280. Epub 2022 Apr 1.

  • Validation of models predicting lymph node involvement probability in patients with prostate cancer Reviewed International journal

    @Leandro Blas, @Masaki Shiota, @Shohei Nagakawa, @Shigehiro Tsukahara, @Takashi Matsumoto, @Keisuke Monji, @Eiji Kashiwagi, @Ario Takeuchi, @Junichi Inokuchi, @Masatoshi Eto

    Int J Urol   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/iju.14802. Epub 2022 Jan 31.

  • Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer Reviewed International journal

    @Shigetomo Yamada, @Masaki Shiota, @Leandro Blas, @Takashi Matsumoto, @Eiji Kashiwagi, @Ario Takeuchi, @Junichi Inokuchi, @Ken-Ichiro Shiga, @Akira Yokomizo, @Masatoshi Eto

    Prostate Int   2022.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.prnil.2021.10.001. Epub 2021 Oct 30.

  • 経口ファーストインクラス低分子RSK阻害剤は前立腺癌のARバリアントと腫瘍増殖を抑制する(An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer)

    Ushijima Miho, Shiota Masaki, Matsumoto Takashi, Kashiwagi Eiji, Inokuchi Junichi, Eto Masatoshi

    Cancer Science   113 ( 5 )   1731 - 1738   2022.5   ISSN:1347-9032

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    リボソームS6キナーゼを標的とするファーストインクラス低分子阻害剤であるPMD-026のYボックス結合タンパク質1(YB-1)/アンドロゲン受容体(AR)シグナルに対する作用と前立腺癌に対する抗腫瘍効果について検討した。in vitro試験において、PMD-026は、高レベルのAR変異体を発現する去勢抵抗性前立腺癌由来の22Rv1細胞におけるYB-1リン酸化、AR V7 mRNAおよびAR変異体の発現を低下させた。前立腺癌由来のAR陰性PC-3細胞やDU145細胞および完全長ARのみを発現するLNCaP細胞に対するPMD-026の細胞毒性は、22Rv1細胞に対する細胞毒性と比較して顕著ではなかった。PMD-026は、単独および第2世代抗アンドロゲン薬であるエンザルタミドやダロルタミドとの併用により、細胞のアポトーシスとG2/M停止を誘導することで細胞増殖を抑制した。22Rv1細胞を免疫不全マウスへ移植したマウス異種移植モデルにおいて、PMD-026とエンザルタミドの併用は、PMD-026単独投与よりも顕著に腫瘍増殖を抑制した。以上より、去勢抵抗性前立腺癌に対する新規リボソームS6キナーゼ阻害剤PMD-026の優れた抗腫瘍効果および抗アンドロゲン薬エンザルタミドとの併用効果が示された。

  • 前立腺癌患者のリンパ節転移確率予測モデルの検証(Validation of models predicting lymph node involvement probability in patients with prostate cancer)

    Blas Leandro, Shiota Masaki, Nagakawa Shohei, Tsukahara Shigehiro, Matsumoto Takashi, Monji Keisuke, Kashiwagi Eiji, Takeuchi Ario, Inokuchi Junichi, Eto Masatoshi

    International Journal of Urology   29 ( 5 )   428 - 434   2022.5   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    日本人の前立腺癌患者コホートにおいて、13種のリンパ節転移確率予測モデルの検証を行った。ロボット支援前立腺全摘除術および拡大骨盤リンパ節郭清術を施行した331例中61例(18.4%)にリンパ節転移を認めた。Receiver operating characteristic(ROC)曲線下面積が最も大きかったのはMemorial Sloan Kettering Cancer Center(MSKCC) web calculator(0.78)、次いでYale formula(0.77)、Brigantiノモグラム2017(0.76)、TosoianらのPartin table(0.75)であったが、これらのモデルの95%信頼区間は重複していた。較正プロットではMSKCC web calculatorとBrigantiノモグラム2017が良好であった。Decision curve analysisではすべての予測モデルがnet benefitを示したが、リンパ節転移リスク<35%においてはMSKCC web calculatorとBrigantiノモグラム2017が最も大きなnet benefitを示した。

  • TESTOSTERONE LEVEL IN SEMINAL VESICLE FLUID IS A BETTER INDICATOR OF SEXUAL FUNCTION THAN SERUM TESTOSTERONE IN PATIENTS WITH PROSTATE CANCER

    Kashiwagi, E; Shiota, M; Monji, K; Lee, K; Matsumoto, T; Takeuchi, A; Inokuchi, J; Eto, M

    JOURNAL OF SEXUAL MEDICINE   19 ( 5 )   S129 - S130   2022.5   ISSN:1743-6095 eISSN:1743-6109

     More details

  • An oral first-in-class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer. International journal

    Miho Ushijima, Masaki Shiota, Takashi Matsumoto, Eiji Kashiwagi, Junichi Inokuchi, Masatoshi Eto

    Cancer science   113 ( 5 )   1731 - 1738   2022.5   ISSN:1347-9032 eISSN:1349-7006

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Ribosomal S6 kinase has been shown to play a key role in cellular resistance to endocrine therapy in prostate cancer through its regulation of YB-1/androgen receptor (AR) signaling. PMD-026, an oral first-in-class small molecule kinase inhibitor, is the first identified ribosomal S6 kinase inhibitor. This study investigated the effect of PMD-026 on YB-1/AR signaling and its antitumor effect in prostate cancer in vitro and in vivo. Castration-resistant prostate cancer 22Rv1 cells that express high-level AR variants were used in this study. The effect of PMD-026 on YB-1/AR signaling was investigated by quantitative real-time PCR and western blot analysis. The effects of PMD-026 on prostate cancer cells were investigated by cytotoxicity analysis, apoptosis assay, and cell cycle assay in vitro and a mouse castration model in vivo. PMD-026 decreased YB-1 phosphorylation as well as AR V7 mRNA and AR variant expressions in 22Rv1 cells. PMD-026 suppressed cell proliferation alone and in combination with the second-generation antiandrogens enzalutamide and darolutamide by inducing cellular apoptosis and G2/M arrest. In a mouse xenograft model, PMD-026 suppressed tumor growth, and the combination of PMD-026 and enzalutamide inhibited tumor growth more prominently than single treatments. Our results demonstrate an excellent antitumor effect of the novel ribosomal S6 kinase inhibitor PMD-026 and the combination effect with the antiandrogen enzalutamide in castration-resistant prostate cancer. These findings warrant a clinical trial of PMD-026 in prostate cancer patients.

    DOI: 10.1111/cas.15280

    Web of Science

    Scopus

    PubMed

    researchmap

  • Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer Invited Reviewed International journal

    @Sotaro Chikamatsu, @Masaki Shiota, @Shigetomo Yamada, @Leandro Blas, @Takashi Matsumoto, @Eiji Kashiwagi, @Junichi Inokuchi, @Ken-Ichiro Shiga, @Akira Yokomizo, @Masatoshi Eto

    Prostate Int   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.prnil.2022.01.001. Epub 2022 Jan 11.

  • Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer Reviewed International journal

    @Masaki Shiota, @Naohiro Fujimoto, @Yohei Sekino, @Shigehiro Tsukahara, @Shohei Nagakawa, @Dai Takamatsu, @Tatsuro Abe, @Fumio Kinoshita, @Shohei Ueda, @Miho Ushijima, @Takashi Matsumoto, @Eiji Kashiwagi, @Junichi Inokuchi, @Takeshi Uchiumi, @Yoshinao Oda, @Masatoshi Eto

    Andrologia   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/and.14307. Epub 2021 Nov 8.

  • Resistance to chemotherapy with gemcitabine associated with hyperexpression of DPYD in muscle invasive bladder cancers

    Tsukahara, S; Shiota, M; Uchiumi, T; Matsumoto, T; Hayashi, T; Nagakawa, S; Eto, M

    CANCER SCIENCE   113   1726 - 1726   2022.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Low FBXW7 expression for bladder cancer is related to poor prognosis, but would benefit from cisplatin.

    Matsumoto, T; Shiota, M; Eto, M

    CANCER SCIENCE   113   1715 - 1715   2022.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • HSD3B1 polymorphism and genomic HSD3B1 aberrations in prostate cancer

    Shiota, M; Fujimoto, N; Sekino, Y; Tsukahara, S; Nagakawa, S; Takamatsu, D; Abe, T; Kinoshita, F; Ueda, S; Matsumoto, T; Kashiwagi, E; Takeuchi, A; Inokuchi, J; Uchiumi, T; Oda, Y; Eto, M

    CANCER SCIENCE   113   1591 - 1591   2022.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer. International journal

    Masaki Shiota, Naohiro Fujimoto, Yohei Sekino, Shigehiro Tsukahara, Shohei Nagakawa, Dai Takamatsu, Tatsuro Abe, Fumio Kinoshita, Shohei Ueda, Miho Ushijima, Takashi Matsumoto, Eiji Kashiwagi, Junichi Inokuchi, Takeshi Uchiumi, Yoshinao Oda, Masatoshi Eto

    Andrologia   54 ( 1 )   e14307   2022.2   ISSN:0303-4569 eISSN:1439-0272

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    This study aimed to investigate the significance of HSD3B1 gene status including germline polymorphism and somatic alterations in prostate cancer. Patients with prostate cancer treated with androgen-deprivation therapy, as well as tissues from metastatic prostate cancer, were included. Genomic DNA was extracted from cancer tissues and whole blood samples, and HSD3B1 (rs1047303, 1245C) was genotyped by Sanger sequencing. The association of HSD3B1 genotype with progression-free survival according to metastatic volume was examined. Copy number alteration and gene expression of HSD3B1 were examined in prostate cancer cells and public datasets. Among 194 patients, 121 and 73 patients were categorized into low- and high-volume diseases respectively. In multivariate analysis, the adrenal-permissive genotype (AC/CC) was significantly associated with increased risk of progression compared with the adrenal-restrictive genotype (AA) in low volume, but not high-volume diseases. Somatic mutation in HSD3B1 was detected at least in two cases of castration-resistant prostate cancer tissues. HSD3B1 amplification and overexpression were detected in castration-resistant prostate cancer cells and tissues. The current findings suggest that both germline and somatic alterations of HSD3B1 may cooperatively promote castration resistance in prostate cancer and HSD3B1 as a promising biomarker for precision medicine, warranting further investigations.

    DOI: 10.1111/and.14307

    Web of Science

    Scopus

    PubMed

    researchmap

  • A genome-wide association study on intravesical recurrence after BCG therapy for non-muscle invasive bladder cancer

    Nagakawa, S; Shiota, M; Fujimoto, N; Yamamoto, Y; Tsukahara, S; Matsumoto, T; Kashiwagi, E; Takeuchi, A; Inokuchi, J; Uchiumi, T; Matsuyama, H; Eto, M

    CANCER SCIENCE   113   1588 - 1588   2022.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors

    Matsumoto Takashi, Shiota Masaki, Yamada Shigetomo, Blas Leandro, Naganuma Hidekazu, Lee Ken, Monji Keisuke, Kashiwagi Eiji, Takeuchi Ario, Inokuchi Junichi, Shiga Ken-ichiro, Yokomizo Akira, Eto Masatoshi

    JMA Journal   5 ( 1 )   83 - 90   2022.1   ISSN:2433328X eISSN:24333298

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japan Medical Association / The Japanese Associaiton of Medical Sciences  

    <p><b>Introduction:</b> Studies on the effect of androgen receptor pathway inhibitors (ARPI), docetaxel (DTX), and radium-223 (Ra-223) after first-line treatment with ARPI in patients with castration-resistant prostate cancer (CRPC) are scarce. This study compared the efficacy of treatment after ARPI for CRPC.</p><p><b>Methods:</b> Patients with CRPC who received ARPI as first-line treatment and different second-line treatments were retrospectively reviewed. Clinicopathological backgrounds and treatment outcomes, including maximum prostate-specific antigen (PSA) decrease, progression-free survival (PFS), and overall survival (OS), were compared between second-line treatments.</p><p><b>Results:</b> In total, 88 patients were enrolled. Forty-one (46.6%), 37 (42.0%), and 10 (11.4%) patients were treated with ARPI, DTX, and Ra-223, respectively. Patients whose PSA levels were not adequately reduced by first-line treatment with ARPI were eventually enrolled in the DTX treatment (P = 0.030). PSA decrease was not significantly different when comparing treatments. PFS in the DTX group was significantly better than in the other two groups (P = 0.023). In multivariate analysis, DTX was an independent prognostic factor for better PFS compared to ARPI (hazard ratio, 95% confidence interval; 0.44, 0.25-0.79, P = 0.006). Subgroup analysis showed a favorable impact of DTX on PFS in patients with Gleason score >8 (interaction P = 0.027) and a PSA decline >50% (interaction P = 0.019) during first-line treatment with ARPI. However, no significant difference in OS was observed between groups of different second-line treatments.</p><p><b>Conclusions:</b> This study suggests that in patients with CRPC, second-line treatment with DTX following progression in patients who received ARPI as first-line treatment is more beneficial compared with second-line treatment with ARPI or Ra-233.</p>

    DOI: 10.31662/jmaj.2021-0163

    Web of Science

    PubMed

    CiNii Research

    researchmap

  • Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients Reviewed International journal

    @Hiroki Kobayashi, @Masaki Shiota, @Nobuaki Sato, @Satoshi Kobayashi, @Takashi Matsumoto, @Keisuke Monji, @Eiji Kashiwagi, @Ario Takeuchi, @Junichi Inokuchi, @Ken-Ichiro Shiga, @Akira Yokomizo, @Masatoshi Eto

    Anticancer Drugs   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/CAD.0000000000001170.

  • Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors Reviewed International journal

    @Takashi Matsumoto, @Masaki Shiota, @Shigetomo Yamada, @Leandro Blas, @Hidekazu Naganuma, @Ken Lee, @Keisuke Monji, @Eiji Kashiwagi, @Ario Takeuchi, @Junichi Inokuchi, @Ken-Ichiro Shiga, @Akira Yokomizo, @Masatoshi Eto

    MA J   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.31662/jmaj.2021-0163. Epub 2021 Dec 28.

  • Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer Reviewed International journal

    @Masaki Shiota, @Leandro Blas, @Satoshi Kobayashi, @Takashi Matsumoto, @Eiji Kashiwagi, @Ario Takeuchi, @Junichi Inokuchi, @Ken-Ichiro Shiga, @Akira Yokomizo, @Masatoshi Eto

    Int J Urol   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/iju.14702. Epub 2021 Sep 22.

  • Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients. International journal

    Hiroki Kobayashi, Masaki Shiota, Nobuaki Sato, Satoshi Kobayashi, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-Ichiro Shiga, Akira Yokomizo, Masatoshi Eto

    Anti-cancer drugs   33 ( 1 )   E541 - E547   2022.1   ISSN:0959-4973 eISSN:1473-5741

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    There are multiple reports on the value of complete blood count (CBC)-related parameters on prognosis in docetaxel-treated castration-resistant prostate cancer (CRPC) patients before the emergence of androgen receptor pathway inhibitors (ARPIs). We investigated the prognostic significance of CBC-related parameters in docetaxel-treated CRPC patients. Patients treated with docetaxel chemotherapy for CRPC between 2008 and 2018 were included. We analyzed the relevance of CBC-related parameters to oncological prognosis in docetaxel chemotherapy, associated with prior use of novel ARPIs. Among 144 Japanese men treated with docetaxel, 49 men (34.0%) had already received ARPI therapy. A high neutrophil-lymphocyte ratio (NLR) was a prognostic factor for poor progression-free survival and overall survival (OS) in both univariate and multivariate analyses. In addition, a low hemoglobin (Hb) level and a high systemic immune-inflammation index (SII) were prognostic factors of poor OS in univariate analysis. Hb level was a prognostic factor of OS in both ARPI-naive and ARPI-treated patients. However, a high NLR and SII were only associated with a poor prognosis in ARPI-naive but not in ARPI-treated patients. Hb, NLR, and SII have been suggested to be prognosticators in docetaxel-treated CRPC patients. The differential prognostic value of NLR and SII between ARPI-naive and ARPI-treated patients may require caution when using these markers in docetaxel-treated CRPC patients.

    DOI: 10.1097/CAD.0000000000001170

    Web of Science

    Scopus

    PubMed

    researchmap

  • 転移性去勢抵抗性前立腺癌に対する一次治療の生存成績に関する予測因子(Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer)

    Shiota Masaki, Blas Leandro, Kobayashi Satoshi, Matsumoto Takashi, Kashiwagi Eiji, Takeuchi Ario, Inokuchi Junichi, Shiga Ken-ichiro, Yokomizo Akira, Eto Masatoshi

    International Journal of Urology   29 ( 1 )   26 - 32   2022.1   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    転移性去勢抵抗性前立腺癌(CRPC)の第一選択治療としてアンドロゲン受容体経路阻害剤(ARPI)やドセタキセルの臨床転帰に関する予測マーカーを検討した。2008年から2018年までにARPIまたはドセタキセルによる治療を受けた転移性CRPCの日本人患者254例(年齢中央値73歳)を対象とした。転移性CRPC患者254例のうち、119例と135例がそれぞれARPIとドセタキセルを受けた。多変量解析の結果、ARPIは、ドセタキセルと比較して、無増悪生存期間(PFS)(ハザード比0.62、95%CI 0.42~0.92、p=0.016)および全生存期間(OS)(ハザード比0.61、95%CI 0.41~0.93、p=0.021のより良い独立した予後因子であった。治療前の前立腺特異抗原レベルとCRPCになるまでの期間は、ARPIとドセタキセルでは、PFSやOSと異なる相関が認められた。CRPCを6ヵ月未満で発症した患者のうち、ARPIを受けた患者のPFS(中央値1.1ヵ月、95%CI 0.2~2.8ヵ月)は、ドセタキセルを受けた患者のPFS(中央値5.0ヵ月、95%CI 1.8~6.7ヵ月、p=0.014)よりも短かった。以上より、ARPIによる一次治療は、予後因子を調整した後でも、ドセタキセルと比較してより良い予後と関連していた。

  • 去勢抵抗性前立腺癌に対するandrogen receptor pathway inhibitorsによる初回治療後の二次治療としての抗癌作用(Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors)

    Matsumoto Takashi, Shiota Masaki, Yamada Shigetomo, Blas Leandro, Naganuma Hidekazu, Lee Ken, Monji Keisuke, Kashiwagi Eiji, Takeuchi Ario, Inokuchi Junichi, Shiga Ken-ichiro, Yokomizo Akira, Eto Masatoshi

    JMA Journal   5 ( 1 )   83 - 90   2022.1   ISSN:2433-328X

     More details

    Language:English   Publisher:(公社)日本医師会  

    去勢抵抗性前立腺癌患者88例を対象とした後ろ向き研究を実施し、androgen receptor pathway inhibitors(ARPI)による初回治療後の2次治療効果を比較した。2次治療によりARPI群41例(年齢中央値76歳)、ドセタキセル(DTX)群37例(年齢中央値74歳)、Ra-223群10例(年齢中央値73歳)に分けて検討した。評価項目は臨床病理学的特徴、前立腺特異抗原(PSA)の最大低下率、無増悪生存期間(PFS)、全生存期間(OS)などとした。その結果、治療群間でPSA減少に有意差は認められなかった。また、DTX群では他2群と比較してPFSが良好であることが示された。また、多変量解析の結果、ARPIと比較してDTXはPFS改善の独立した予後因子であった(ハザード比0.44、P=0.006)。サブグループ解析の結果、ARPIによる初回治療時、グリソンスコア>8であった患者、PSA低下率>50%の患者において、DTXがPFSへ好影響をもたらすことが示された(交互作用P=0.027、P=0.019)。しかし、二次治療間でOSに有意差は認められなかった。以上のように、ARPIによる初回治療後の二次治療として、DTXはARPIまたはRa-233と比較してより有益であることが示唆された。

  • Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective

    Takashi Matsumoto, Masaki Shiota, Leandro Blas, Masatoshi Eto

    Cancer Management and Research   14   2389 - 2397   2022   ISSN:1179-1322 eISSN:1179-1322

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Informa UK Limited  

    DOI: 10.2147/CMAR.S326114

    Web of Science

    Scopus

    PubMed

    researchmap

  • Prognostic Value of Lower Tract Urinary Symptoms in Clinically Regional Lymph Node-positive Prostate Cancer Reviewed International journal

    @Leandro Blas, @Kosuke Ieiri, @Masaki Shiota, @Shohei Nagakawa, @Shigehiro Tsukahara, @Takashi Matsumoto, @Eiji Kashiwagi, @Ario Takeuchi, @Junichi Inokuchi, @Ken-Ichiro Shiga, @Akira Yokomizo, @Masatoshi Eto

    Anticancer Res   2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.15373.

  • The impact of single-nucleotide polymorphisms on intravesical recurrence after bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer in a genome-wide association study Reviewed International journal

    2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.urolonc.2021.05.034. Epub 2021 Jun 29.

  • Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer Reviewed International journal

    @Leandro Blas, @Masaki Shiota, @Shigetomo Yamada, @Kosuke Ieiri, @Shohei Nagakawa, @Shigehiro Tsukahara, @Takashi Matsumoto, @Eiji Kashiwagi, @Ario Takeuchi, @Junichi Inokuchi, @Ken-Ichiro Shiga, @Akira Yokomizo, @Masatoshi Eto

    Anticancer Res   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/anticanres.15183.

  • Prognostic impact of prior local therapy in castration-resistant prostate cancer Reviewed International journal

    @Mikifumi Koura, @Masaki Shiota, @Shohei Ueda, @Takashi Matsumoto, @Satoshi Kobayashi, @Keisuke Monji, @Eiji Kashiwagi, @Ario Takeuchi, @Junichi Inokuchi, @Ken-Ichiro Shiga, @Akira Yokomizo, @Masatoshi Eto

    Jpn J Clin Oncol   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/jjco/hyab019.

  • Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study Reviewed International journal

    2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.prnil.2020.12.001. Epub 2020 Dec 30.

  • Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors Reviewed International journal

    @Asako Machidori, @Masaki Shiota, @Satoshi Kobayashi, @Takashi Matsumoto, @Keisuke Monji, @Eiji Kashiwagi, @Ario Takeuchi, @Ryosuke Takahashi, @Junichi Inokuchi, @Masatoshi Eto

    Urol Oncol   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.urolonc.2020.09.036. Epub 2020 Oct 17.

  • Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer Reviewed International journal

    @Masaki Shiota, @Naohiro Fujimoto, @Takashi Matsumoto, @Shigehiro Tsukahara, @Shohei Nagakawa, @Shohei Ueda, @Miho Ushijima, @Eiji Kashiwagi, @Ario Takeuchi, @Junichi Inokuchi, @Takeshi Uchiumi, @Masatoshi Eto

    Front Oncol   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fonc.2021.697955. eCollection 2021.

  • Gene amplification of YB-1 in castration-resistant prostate cancer in association with aberrant androgen receptor expression Reviewed International journal

    @Masaki Shiota, @Yohei Sekino, @Shigehiro Tsukahara, @Tatsuro Abe, @Fumio Kinoshita, @Kenjiro Imada, @Shohei Ueda, @Miho Ushijima, @Shohei Nagakawa, @Takashi Matsumoto, @Eiji Kashiwagi, @Ario Takeuchi, @Junichi Inokuchi, @Takeshi Uchiumi, @Yoshinao Oda, @Masatoshi Eto

    Cancer Sci   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.14695. Epub 2020 Nov 24.

  • Genomic characteristics revealed by targeted exon sequencing of testicular germ cell tumors in Japanese men Reviewed International journal

    @Takashi Matsumoto, @Masaki Shiota, @Takeshi Uchiumi, @Shohei Ueda, @Shigehiro Tsukahara, @Takahiro Toshima. @Shinya Matsumoto, @Nozomi Noda, @Masatoshi Eto, @Dongchon Kang

    international journal of urology   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: https://doi.org/10.1111/iju.14396

    Other Link: https://onlinelibrary.wiley.com/doi/abs/10.1111/iju.14396

  • Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity Invited Reviewed International journal

    @Takashi Matsumoto, @Takeshi Uchiumi, @Keisuke Monji, Mikako Yagi, @Daiki Setoyama, @Rie Amamoto, @Yuichi Matsushima, @Masaki Shiota, @Masatoshi Eto, @Dongchon Kang

    ONCOGENESIS   6   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41389-017-0009-3

  • Serum depletion induced cancer stem cell-like phenotype due to nitric oxide synthesis in oncogenic HRas transformed cells Invited Reviewed International journal

    @Keisuke Monji, @Takeshi Uchiumi, @Saki Hoshizawa, @Mikako Yagi, @Takashi Matsumoto, @Daiki Setoyama, @Yuichi Matsushima, @Kazuhito Gotoh, @Rie Amamoto, @Donchon Kang

    ONCOTARGET   7 ( 46 )   75221 - 75234   2016.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.18632/oncotarget.12117

▼display all

Books

  • Prostate Cancer related to HBOC

    Takashi Matsumoto, Masaki Shiota

    Japanese Journal of Urological Surgery  2022.4 

     More details

  • current status and future prospects of blood-based liquid biopsy in urothelial carcinoma

    Takashi Matsumoto( Role: Sole author)

    2022.1 

     More details

Presentations

▼display all

MISC

  • Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report. Reviewed

    @Kaitsumaru M, @Shiota M, @Takamatsu D, #Blas L, @Matsumoto T, @Inokuchi J, @Oda Y, @Eto M:

    Int Cancer Conf   2023.1

     More details

    Language:English   Publishing type:Internal/External technical report, pre-print, etc.  

  • Construction of An Image Conversion Model to Generate 3D Organ Model Images from Robot-assisted Surgery Endoscopic Images

    月野圭治, 月野圭治, 宮内翔子, 小林聡, 小栗晋, 牟田口淳, 塚原茂大, 後藤駿介, 松元崇, 門司恵介, 塩田真己, 猪口淳一, 沖英次, 沖英次, 倉爪亮, 江藤正俊

    日本コンピュータ外科学会誌(Web)   25 ( 3 )   2023   ISSN:1884-5770

  • 泌尿器科領域におけるAI技術の応用 膀胱内視鏡におけるAI診断

    牟田口 淳, 諸岡 健一, 楳原 愛子, 宮内 翔子, 木下 史生, 長沼 英和, 松元 崇, 李 賢, 門司 恵介, 柏木 英志, 武内 在雄, 塩田 真己, 猪口 淳一, 江藤 正俊

    日本腎泌尿器疾患予防医学研究会誌   30 ( 1 )   34 - 37   2022.3   ISSN:1347-5010

     More details

    Language:Japanese   Publisher:日本腎泌尿器疾患予防医学研究会  

  • The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: where is the clinically relevant hotspot for prostate cancer? Reviewed

    @Takashi Matsumoto, @Masaki Shiota

    translational andrology and urology   2020.10

     More details

    Language:English   Publishing type:Article, review, commentary, editorial, etc. (scientific journal)  

    DOI: 10.21037/tau-20-866

    Other Link: http://tau.amegroups.com/article/view/41813/html

Industrial property rights

Patent   Number of applications: 3   Number of registrations: 0
Utility model   Number of applications: 0   Number of registrations: 0
Design   Number of applications: 0   Number of registrations: 0
Trademark   Number of applications: 0   Number of registrations: 0

Professional Memberships

  • The Japanese urological association

  • Japan Society of Urological Oncology

  • Japanese Society of Endourology and Robotics

Committee Memberships

  • 日本泌尿器腫瘍学会   代議員  

    2024.3   

      More details

  • 日本泌尿器科学会   NCD運営委員会  

    2023.6   

      More details

    Committee type:Academic society

    researchmap

  • 西日本泌尿器科学会   西日本泌尿器科学会選挙管理委員  

    2022.8   

      More details

Research Projects

  • 尿/血液循環腫瘍DNAを用いた膀胱癌の高感度、高特異度PCRモニタリング法の開発

    2024 - 2025

    科学研究費助成事業 

      More details

    Authorship:Principal investigator  Grant type:Competitive funding other than Grants-in-Aid for Scientific Research

  • 筋層浸潤性尿路上皮がん患者を対象としたニボルマブ術後補助療法の日本における 治療実態研究(ANNIVERSARY試験)

    2023.5 - 2027.2

      More details

    Authorship:Principal investigator 

  • 尿/血液循環腫瘍 DNAを用いた泌尿器癌のモニタリング法の開発

    2023.4 - 2025.3

      More details

    Authorship:Principal investigator 

  • 進行腎細胞癌に対するPD-1経路阻害薬の継続と休止に関するランダム化比較第Ⅲ相試験

    2023 - 2025

    革新的がん医療実用化研究事業

      More details

    Authorship:Principal investigator  Grant type:Contract research

  • 尿/血液循環腫瘍DNAを用いた膀胱癌の高感度、高特異度PCRモニタリング法の開発

    2023 - 2024

    鈴木泌尿器医学振興財団助成

      More details

    Authorship:Principal investigator  Grant type:Contract research

  • 尿/血液循環腫瘍DNAを用いた泌尿器癌のモニタリング法の開発

    2023

    橋渡し研究プログラム シーズA

      More details

    Authorship:Principal investigator  Grant type:Contract research

  • 膀胱癌におけるFBXW7の治療抵抗性獲得の解明およびctDNAによる予後予測

    2022.4 - 2027.3

      More details

    Authorship:Principal investigator 

  • 膀胱癌におけるFBXW7の治療抵抗性獲得の解明およびctDNAによる予後予測

    Grant number:22K16791  2022 - 2026

    日本学術振興会  科学研究費助成事業  若手研究

    松元 崇

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    膀胱癌は様々な癌種の中でも変異率が高く、不均一な細胞集団であり、治療抵抗性に寄与する細胞集団が存在すると考えられる。膀胱癌患者の生存率向上のためには、致死性の腫瘍細胞クローンを特定することが必要である。FBXW7という遺伝子の発現低下や変異のある膀胱癌患者は全生期間が短いことが分かっている。本研究では、治療抵抗性に寄与する致死性の細胞集団としてFBXW7の低発現や変異に着目し、血中循環腫瘍(ctDNA)中のFBXW7の変異を同定することで、低侵襲的に患者の予後を予測できるか検討を行う。

    CiNii Research

  • JCOG1905: 進行性腎細胞癌に対するPD-1経路阻害薬の継続と休止に関するランダム化比較第III相試験

    2020.7 - 2030.7

    九州大学 泌尿器科 

      More details

    Authorship:Principal investigator 

    進行性(切除不能もしくは転移性)淡明細胞型腎細胞癌に対し、免疫チェックポイント阻害薬(PD-1経路阻害薬)を投与し、開始後24週時点で増悪およびコントロール不能の有害事象を認めていない患者を対象に、PD-1経路阻害薬を休止する治療法の臨床的有用性を、標準治療であるPD-1経路阻害薬を継続投与する治療法とのランダム化比較にて検証する。

▼display all

Class subject

  • 尿路性感染症

    2024.10 - 2025.3   Second semester

Travel Abroad

  • 2018.4 - 2020.3

    Staying countory name 1:Canada   Staying institution name 1:University of British Columbia